Publications by authors named "Thomas C Stock"

Claim this Profile
P
Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study.
Nicolino Ruperto, Hermine I Brunner, Zbigniew Zuber, Nikolay Tzaribachev, Daniel J Kingsbury, Thomas C Stock

Pediatr Rheumatol Online J· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extended-Release Once-Daily Formulation of Tofacitinib: Evaluation of Pharmacokinetics Compared With Immediate-Release Tofacitinib and Impact of Food.
Manisha Lamba, Rong Wang, Tracey Fletcher, Christine Alvey, Joseph Kushner, Thomas C Stock

J Clin Pharmacol· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of CE-224,535, an antagonist of P2X7 receptor, in treatment of patients with rheumatoid arthritis inadequately controlled by methotrexate.
Thomas C Stock, Bradley J Bloom, Nathan Wei, Saliha Ishaq, Won Park

J Rheumatol· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in the treatment of patients with rheumatoid arthritis in a randomized, double-blind placebo-controlled trial.
Dona L Fleishaker, Juan A Garcia Meijide, Andriy Petrov, Michael David Kohen, Xin Wang, Thomas C Stock

Arthritis Res Ther· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis